The association between beta‐blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias. Issue 2 (14th October 2022)

• Record Type: Journal Article
• Authors: Gilstrap, Lauren; Cohen, Andrew; Ouellet, Gregory M.; Goyal, Parag; Gladders, Barbara; Flint, Danette; Skinner, Jonathan
• Is Part Of: Journal of the American Geriatrics Society. Volume 71:Issue 2(2023)
• Page Start: 404
• Page End: 413
• Publication Date: 2022-10-14
• Subjects: Alzheimer's disease and related dementia -- beta‐blockers -- dementia -- heart failure; Geriatrics -- Periodicals; 618.97
• DOI: 10.1111/jgs.18086
• Languages: English
• ISSNs: 0002-8614

Abstract

Abstract: Background: Contemporary patients with heart failure with reduced ejection fraction (HFrEF) are older and have a higher prevalence of cognitive impairment than those studied in trials. The risk/benefit trade‐off of routine beta‐blocker (BB) use in patients with HFrEF and Alzheimer's disease and related dementias (ADRD) has not been explored. This study aimed to determine the association between BB use and outcomes among patients with HFrEF and ADRD. Methods: Using a random 40% sample of Medicare Parts A, B, and D data we identified patients with ≥1 hospitalization for HFrEF between 2008 and 2018. Each patient was classified based on BB use prior to admission and after discharge. Outcomes include 90‐day and 1‐year mortality and readmission. Results: Between 2008 and 2018, we identified 357, 030 patients hospitalized with HFrEF; 12.7% had ADRD. Patients with HFrEF and ADRD had higher 90‐day and 1‐year mortality compared to patients with HFrEF‐only. Among patients admitted on a BB, 60.5% of patients with HFrEF‐only were continued on therapy after discharge, compared to 56.8% of patients with HFrEF and ADRD. Discontinuing BB was associated with a 2.2‐fold higher risk of 90‐day mortality ( p < 0.001) among patients with HF‐only and a 2.‐ fold higher risk of 90‐day mortality ( p < 0.001) among patients with HFrEF + ADRD. Not starting a BB was associated with a 1.8‐fold higher risk of 90‐day mortality ( p < 0.001) among patients with HFrEF‐only and a 1.7‐fold higher risk of 90‐day mortality ( p < 0.001) among patients with HFrEF + ADRD. Similar risks were seen at 1 year. Conclusions: BB therapy is associated with significantly lower short and long‐term mortality rates among all patients with HFrEF; the magnitude of these associated benefits appear at least as large in patients with HFrEF and ADRD compared to patients with HFrEF‐only.